- Coronado Biosciences (CNDO) shares jump 12.4% AH after the company releases interim data for a pilot study of oral CNDO-201 to treat autism.
- In the first 5 patients that completed the double-blind, randomized, placebo-controlled cross-over study, a statistically significant separation from the placebo in favor of CNDO-201 was demonstrated in 3 measures of the disease. Treatment was well tolerated, the study found.
- The study is ongoing and final results are expected in mid-2014.
Coronado Biosciences +12.4% AH on interim CNDO-201 study
Dec 12 2013, 17:00 ET